Effects of the dutasteride and sildenafil association in the penis of a benign prostatic hyperplasia animal model

References

• Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016;43:289–297.
   PubMed Web of Science ®Google Scholar
• Erdemir F, Harbin A, Hellstrom WJ. 5-alpha reductase inhibitors and erectile dysfunction: the connection. J Sex Med. 2008;5:2917–2924.
   PubMed Web of Science ®Google Scholar
• Alcaraz A, Carballido-Rodriguez J, Unda-Urzaiz M, et al. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment-the QUALIPROST study. Int Urol Nephrol. 2016;48:645–656.
   PubMed Web of Science ®Google Scholar
• Madersbacher S, Alivizatos G, Nordling J, et al. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol. 2004;46:547–554.
   PubMed Web of Science ®Google Scholar
• McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185:1793–1803.
   PubMed Web of Science ®Google Scholar
• Alcantara-Montero A, Brenes-Bermudez FJ. Finasteride or dutasteride for the pharmacological treatment for male lower urinary tract symptoms due to benign prostatic hyperplasia? Actas Urol Esp. 2016; 40:268–269.
   PubMed Web of Science ®Google Scholar
• Shigehara K, Koh E, Sakamoto J, et al. Effects of dutasteride on lower urinary tract symptoms and general health in men with benign prostatic hypertroplasia and hypogonadism: a prospective study. Aging Male. 2014;17:51–56.
   PubMed Web of Science ®Google Scholar
• Shigehara K, Miyagi T, Nakashima T, et al. Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction. Aging Male. 2016;19:128–133.
   PubMed Web of Science ®Google Scholar
• Wada N, Hashizume K, Matsumoto S, et al. Dutasteride improves bone mineral density in male patients with lower urinary tract symptoms and prostatic enlargement: a preliminary study. Aging Male. 2016;19:12–14.
   PubMed Web of Science ®Google Scholar
• Qian X, Yu G, Qian Y, et al. Efficacy of 5alpha-reductase inhibitors for patients with large benign prostatic hyperplasia (>80 mL) after transurethral resection of the prostate. Aging Male. 2015;18:238–243.
   PubMed Web of Science ®Google Scholar
• Maeda T, Kikuchi E, Hasegawa M, et al. A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride. Aging Male. 2016;19:111–116.
   PubMed Web of Science ®Google Scholar
• Traish A, Haider KS, Doros G, et al. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. Horm Mol Biol Clin Investig. 2017;30.
   PubMed Web of Science ®Google Scholar
• Traish AM, Haider KS, Doros G, et al. Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia. Horm Mol Biol Clin Investig. 2015;23:85–96.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Casabe A, Glina S, et al. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo. Int J Urol. 2015;22:582–587.
   PubMed Web of Science ®Google Scholar
• Serati M, Andersson KE, Dmochowski R, et al. Systematic review of combination drug therapy for non-neurogenic lower urinary tract symptoms. Eur Urol. 2019;75:129–168.
   PubMed Web of Science ®Google Scholar
• Watanabe D, Yamashita A, Miura K, et al. Effects on sexual function in Japanese patients with benign prostatic hyperplasia upon switching from combination therapy with alpha1 blocker and dutasteride to combination therapy with tadalafil and dutasteride. Aging Male. 2018;20:1–6.
   Web of Science ®Google Scholar
• Scaglione F, Donde S, Hassan TA, et al. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction: pharmacology and clinical impact of the sildenafil citrate orodispersible tablet formulation. Clin Ther. 2017;39:370–377.
   PubMed Web of Science ®Google Scholar
• Leoni LA, Leite GS, Wichi RB, et al. Sildenafil: two decades of benefits or risks? Aging Male. 2013;16:85–91.
   PubMed Web of Science ®Google Scholar
• Li H, Bai G, Zhang X, et al. Effects of two different dosages of sildenafil on patients with erectile dysfunction. Am J Mens Health. 2017;11:525–530.
   PubMed Web of Science ®Google Scholar
• Palmerini CA, Zucchi A, Fioretti F, et al. Erectile dysfunction and NO: variations of NO penile blood levels before and after sildenafil treatment. Int J Impot Res. 2009;21:321–325.
   PubMed Web of Science ®Google Scholar
• Da Silva MHA, Costa WS, Fj BS, et al. The corpus cavernosum after treatment with dutasteride or finasteride: a histomorphometric study in a benign prostatic hyperplasia rodent model. Asian J Androl. 2018;20:505–510.
   PubMed Web of Science ®Google Scholar
• Felix-Patricio B, Medeiros JL, Jr., De Souza DB, et al. Penile histomorphometrical evaluation in hypertensive rats treated with sildenafil or enalapril alone or in combination: a comparison with normotensive and untreated hypertensive rats. J Sex Med. 2015;12:39–47.
   PubMed Web of Science ®Google Scholar
• Lujan M, Ferruelo A, Paez A, et al. Prostate apoptosis after doxazosin treatment in the spontaneous hypertensive rat model. BJU Int. 2004;93:410–414.
   PubMed Web of Science ®Google Scholar
• Wang D, Zha X, Nagase K, et al. Effects of the 5alpha-reductase inhibitor dutasteride on rat prostate alpha1A-adrenergic receptor and its mediated contractility. Urology. 2015;85:704 e9–704 e14.
   PubMed Web of Science ®Google Scholar
• Ribeiro CT, Costa WS, Sampaio FJB, et al. Evaluation of the effects of chronic stress applied from the prepubertal to the adult stages or only during adulthood on penile morphology in rats. Stress. 2019;22:248–255.
   PubMed Web of Science ®Google Scholar
• Sena A. D S M D, Vargas RA, Souza D. B D, et al. Morphometric study of the corpus cavernosum after anabolic androgenic steroid administration in pubertal and adult rats. Acta Cir Bras. 2015;30:478–483.
   PubMed Web of Science ®Google Scholar
• Furriel A, Campos-Silva P, Silva PC, et al. Diets rich in saturated and polyunsaturated fatty acids induce morphological alterations in the rat ventral prostate. PLoS One. 2014;9:e102876.
   PubMed Web of Science ®Google Scholar
• Vargas RA, Oliveira LP, Frankenfeld S, et al. The prostate after administration of anabolic androgenic steroids: a morphometrical study in rats. Int Braz J Urol. 2013;39:675–682.
   PubMed Web of Science ®Google Scholar
• Felix-Patricio B, De Souza DB, Gregorio BM, et al. How to quantify penile corpus cavernosum structures with histomorphometry: comparison of two methods. Biomed Res Int. 2015;2015:832156.
   PubMed Web of Science ®Google Scholar
• Miranda AF, Gallo CB, De Souza DB, et al. Effects of castration and late hormonal replacement in the structure of rat corpora cavernosa. J Androl. 2012;33:1224–1232.
   PubMedGoogle Scholar
• Montes GS. Structural biology of the fibres of the collagenous and elastic systems. Cell Biol Int. 1996;20:15–27.
   PubMed Web of Science ®Google Scholar
• Corona G, Tirabassi G, Santi D, et al. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology. 2017;5:671–678.
   PubMed Web of Science ®Google Scholar
• Kilic S, Kolukcu E, Erdemir F, et al. The effects of oral 5-alpha reductase inhibitors on penile intracavernosal pressures and penile morphology in rat model. Urol J. 2018;16:205–211.
   Web of Science ®Google Scholar
• Oudot A, Oger S, Behr-Roussel D, et al. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat. BJU Int. 2012;110:1352–1358.
   PubMed Web of Science ®Google Scholar
• Ko WJ, Han HH, Ham WS, et al. Daily use of sildenafil 50mg at night effectively ameliorates nocturia in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: an exploratory multicenter, double-blind, randomized, placebo-controlled study. Aging Male. 2017;20:81–88.
   PubMed Web of Science ®Google Scholar
• Costa WS, Carrerete FB, Horta WG, et al. Comparative analysis of the penis corpora cavernosa in controls and patients with erectile dysfunction. BJU Int. 2006;97:567–569.
   PubMed Web of Science ®Google Scholar
• Kovanecz I, Rivera S, Nolazco G, et al. Separate or combined treatments with daily sildenafil, molsidomine, or muscle-derived stem cells prevent erectile dysfunction in a rat model of cavernosal nerve damage. J Sex Med. 2012;9:2814–2826.
   PubMed Web of Science ®Google Scholar
• de Souza DB, Silva D, Cortez CM, et al. Effects of chronic stress on penile corpus cavernosum of rats. J Androl. 2012;33:735–739.
   PubMedGoogle Scholar
• Pinsky MR, Gur S, Tracey AJ, et al. The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med. 2011;8:3066–3074.
   PubMed Web of Science ®Google Scholar
• El-Sakka AI, Yassin AA. Amelioration of penile fibrosis: myth or reality. J Androl. 2010;31:324–335.
   PubMed Web of Science ®Google Scholar
• Maia RS, Babinski MA, Figueiredo MA, et al. Concentration of elastic system fibers in the corpus cavernosum, corpus spongiosum, and tunica albuginea in the rabbit penis. Int J Impot Res. 2006;18:121–125.
   PubMed Web of Science ®Google Scholar
• Pinheiro AC, Costa WS, Cardoso LE, et al. Organization and relative content of smooth muscle cells, collagen and elastic fibers in the corpus cavernosum of rat penis. J Urol. 2000;164:1802–1806.
   PubMed Web of Science ®Google Scholar
• Abidu-Figueiredo M, Ribeiro IC, Chagas MA, et al. The penis in diabetes: structural analysis of connective tissue and smooth muscle alterations in a rabbit model. BJU Int. 2011;108:400–404.
   PubMed Web of Science ®Google Scholar
• Abidu-Figueiredo M, Costa WS, Chagas MA, et al. Age-related changes in the concentration of elastic fibers in different regions of the rabbit penis. Acta Cir Bras. 2013;28:378–384.
   PubMed Web of Science ®Google Scholar
• Costa WS, Felix B, Cavalcanti AG, et al. Structural analysis of the corpora cavernosa in patients with ischaemic priapism. BJU Int. 2010;105:838–841.
   PubMed Web of Science ®Google Scholar
• Lewis KG, Bercovitch L, Dill SW, et al. Acquired disorders of elastic tissue: part I. Increased elastic tissue and solar elastotic syndromes. J Am Acad Dermatol. 2004;51:1–21.
   PubMed Web of Science ®Google Scholar
• Favilla V, Russo GI, Privitera S, et al. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. Aging Male. 2016;19:175–181.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Manyak MJ, Palacios-Moreno JM, et al. A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int. 2018;121:647–658.
   PubMed Web of Science ®Google Scholar
• Kosilov K, Kuzina I, Kuznetsov V, et al. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage. Aging Male. 2018;21:121–129.
   PubMed Web of Science ®Google Scholar
• Kosilov K, Loparev S, Ivanovskaya M, et al. Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with tamsulosin. Aging Male. 2015;18:44–48.
   PubMed Web of Science ®Google Scholar
• Kosilov K, Loparev S, Kuzina I, et al. The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms. Aging Male. 2017;20:39–44.
   PubMed Web of Science ®Google Scholar